MCID: BCT022
MIFTS: 53

Bacterial Infectious Disease

Categories: Infectious diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Bacterial Infectious Disease

MalaCards integrated aliases for Bacterial Infectious Disease:

Name: Bacterial Infectious Disease 11 14
Bacterial Disease or Disorder 33
Disease Caused by Bacteria 33
Bacterial Infection Nos 33
Bacterial Infections 43

Classifications:



External Ids:

Disease Ontology 11 DOID:104
MeSH 43 D001424
NCIt 49 C2890
SNOMED-CT 68 87628006
ICD10 31 A49 A49.9
ICD11 33 520429137
UMLS 71 C0004623

Summaries for Bacterial Infectious Disease

Disease Ontology: 11 A disease by infectious agent that results in infection, has material basis in Bacteria.

MalaCards based summary: Bacterial Infectious Disease, also known as bacterial disease or disorder, is related to commensal bacterial infectious disease and primary bacterial infectious disease. An important gene associated with Bacterial Infectious Disease is CRP (C-Reactive Protein), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Esomeprazole and Cephalexin have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and eye, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Bacterial Infectious Disease

Diseases related to Bacterial Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1319)
# Related Disease Score Top Affiliating Genes
1 commensal bacterial infectious disease 33.1 TNF TLR4 TLR2 MYD88 IL6 IL1B
2 primary bacterial infectious disease 33.1 TNF TLR4 TLR2 NOD2 MYD88 IL6
3 actinomycosis 32.7 TNF IL10 CRP
4 listeriosis 32.7 TNF TLR2 MYD88 IL6 IL1B IL10
5 tularemia 32.7 TNF TLR4 TLR2 MYD88 IL6 IL1B
6 endocarditis 32.6 TNF TLR2 IL6 IL17A IL10 IFNG
7 sickle cell anemia 32.6 TNF IL6 CSF3 CRP
8 bacterial meningitis 32.5 TNF TLR4 TLR2 IL1B IL10 CXCL8
9 leukocyte adhesion deficiency, type i 32.5 IL17A CSF3 CCR6
10 paratyphoid fever 32.5 TNF IL1B IFNG CRP
11 infective endocarditis 32.5 IL6 CXCL8 CRP CCR6
12 leptospirosis 32.5 TNF TLR2 IL6 IL1B IL10 IFNG
13 lyme disease 32.5 TNF TLR2 IL6 IL1B IL17A CRP
14 typhoid fever 32.5 TNF TLR4 IL6 IL1B IFNG CRP
15 tetanus 32.5 TNF IL6 IL1B IL10 IFNG CRP
16 trachoma 32.5 TNF IL6 IL17A IL10
17 legionellosis 32.5 TNF TLR4 TLR2 NOD1 MYD88 IL6
18 syphilis 32.5 TNF TLR2 IL17A CRP CCR6
19 brucellosis 32.5 TNF TLR4 IL6 IL17A IL10 IFNG
20 cholera 32.5 TNF IL6 IL1B IL10 IFNG CXCL8
21 neutropenia 32.5 TNF TLR4 IL6 IL1B IL10 IFNG
22 melioidosis 32.5 TNF TLR4 TLR2 NOD2 IL6 IL10
23 common variable immunodeficiency 32.5 TNF TLR2 NOD2 IL6 IL1B IL10
24 severe congenital neutropenia 3 32.5 ELANE CSF3 CAMP
25 plague 32.5 TNF TLR4 TLR2 MYD88 IL6 IL1B
26 gas gangrene 32.5 TNF IL6 CRP
27 shigellosis 32.5 IL1B IL10 DEFB1 CCR6 CAMP
28 severe congenital neutropenia 32.4 TNF ELANE CSF3 CAMP
29 macs syndrome 32.4 TNF IL10 IFNG
30 q fever 32.4 TNF TLR4 TLR2 NOD2 MYD88 IL6
31 whim syndrome 1 32.4 ELANE CSF3 CCR6
32 toxic shock syndrome 32.4 TNF TLR4 TLR2 IL6 IL1B IL10
33 bacterial sepsis 32.4 TNF TLR4 TLR2 MYD88 IL6 IL1B
34 chlamydia 32.4 TNF TLR4 TLR2 NOD1 IL6 IL1B
35 tonsillitis 32.4 TNF TLR4 TLR2 IL6 IL1B IL10
36 neutropenia, severe congenital, 3, autosomal recessive 32.4 ELANE CSF3
37 leprosy 3 32.4 TNF TLR4 TLR2 NOD2 IL6 IL1B
38 common cold 32.4 TNF IL6 IL1B IL17A IL10 CXCL8
39 blepharitis 32.4 TNF IL6 IL1B IL17A CXCL8 CCR6
40 mycobacterium tuberculosis 1 32.4 TNF TLR4 TLR2 NOD2 MYD88 IL6
41 salmonellosis 32.3 TNF TLR4 TLR2 NOD2 NOD1 MYD88
42 severe cutaneous adverse reaction 32.3 TNF IL6 IFNG CRP CCR6
43 chronic granulomatous disease 32.3 TNF IL1B IFNG CSF3
44 pyoderma 32.3 TNF NOD2 IL1B IL17A CXCL8 CSF3
45 urinary tract infection 32.3 TNF TLR4 TLR2 IL6 IL1B IL10
46 acute proliferative glomerulonephritis 32.3 TNF IL1B IL17A CRP CCR6
47 inflammatory diarrhea 32.3 IL1B IL17A IL10 CXCL8
48 pyoderma gangrenosum 32.3 TNF NOD2 IL1B CXCL8 CSF3 CCR6
49 cystic fibrosis 32.2 TNF TLR4 TLR2 NOD2 MYD88 IL6
50 hyper ige syndrome 32.2 TLR4 TLR2 IL6 IL17A IL10 IFNG

Graphical network of the top 20 diseases related to Bacterial Infectious Disease:



Diseases related to Bacterial Infectious Disease

Symptoms & Phenotypes for Bacterial Infectious Disease

GenomeRNAi Phenotypes related to Bacterial Infectious Disease according to GeneCards Suite gene sharing:

25 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.33 CXCL8 IL10 IL17A IL1B MYD88 NOD1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.33 CXCL8 IL10 IL17A IL1B MYD88 NOD1
3 no effect GR00402-S-1 10.17 CAMP CCR6 CRP CSF3 CXCL8 DEFB1
4 no effect GR00402-S-2 10.17 CAMP CCR6 CRP CSF3 DEFB1 DEFB4A
5 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.05 IL10
6 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.05 IL10
7 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.05 CRP
8 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.05 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.05 TLR4
10 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.05 CRP
11 Increased shRNA abundance (Z-score > 2) GR00366-A-148 10.05 CRP
12 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.05 IL10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.05 CRP IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.05 IL10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.05 IL10 NOD2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.05 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.05 TLR4
18 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.05 NOD2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.05 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.05 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.05 CRP
22 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.05 IL10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.05 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-68 10.05 IL10 TLR4
25 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.05 IL10
26 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.05 IL10

MGI Mouse Phenotypes related to Bacterial Infectious Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.3 CAMP CCR6 CRP CSF3 DEFB1 DEFB4A
2 homeostasis/metabolism MP:0005376 10.25 CCR6 CRP ELANE IFNG IL10 IL17A
3 neoplasm MP:0002006 10.11 ELANE IFNG IL10 IL1B IL6 MYD88
4 liver/biliary system MP:0005370 10.03 IFNG IL10 IL17A IL6 MYD88 TLR2
5 digestive/alimentary MP:0005381 10.02 IFNG IL10 IL17A IL6 MYD88 NOD2
6 hematopoietic system MP:0005397 9.89 CAMP CCR6 CSF3 DEFB4A ELANE IFNG
7 respiratory system MP:0005388 9.86 IFNG IL10 IL17A IL6 MYD88 TLR2
8 skeleton MP:0005390 9.85 IFNG IL10 IL17A IL1B IL6 MYD88
9 integument MP:0010771 9.36 CSF3 ELANE IFNG IL10 IL17A IL1B

Drugs & Therapeutics for Bacterial Infectious Disease

Drugs for Bacterial Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 365)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
2
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
3
Roxithromycin Approved, Investigational, Withdrawn Phase 4 80214-83-1 6915744
4
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
5
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
6
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
7
Ibuprofen Approved Phase 4 15687-27-1 3672
8
Metronidazole Approved Phase 4 443-48-1, 69198-10-3 4173
9
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 2826718
10
Polymyxin B Approved, Vet_approved Phase 4 1405-20-5, 1404-26-8 4868
11
Minocycline Approved, Investigational Phase 4 10118-90-8, 13614-98-7 54675783 5281021
12
Doripenem Approved, Investigational Phase 4 148016-81-3 73303
13
Azithromycin Approved Phase 4 83905-01-5 447043
14
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
15
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
16
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
17
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
18
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
19
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
20
Tetracycline Approved, Vet_approved, Withdrawn Phase 4 60-54-8 5353990
21
Clarithromycin Approved Phase 4 81103-11-9 84029
22
Rabeprazole Approved, Investigational Phase 4 117976-89-3, 117976-90-6 5029
23
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
24
Cefadroxil Approved, Vet_approved, Withdrawn Phase 4 66592-87-8, 50370-12-2 47965
25
Clindamycin Approved, Vet_approved Phase 4 18323-44-9, 24729-96-2 29029
26
Retapamulin Approved Phase 4 224452-66-8 6918462
27
Carbamide peroxide Approved Phase 4 124-43-6
28
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
29
Histamine Approved, Investigational Phase 4 51-45-6 774
30
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
31
Promethazine Approved, Investigational Phase 4 60-87-7 4927
32
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
33
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
34
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
35
Tazobactam Approved Phase 4 89786-04-9 123630
36
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
37
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 441130
38
Piperacillin Approved Phase 4 66258-76-2 43672
39
Iodine Approved, Investigational Phase 4 7553-56-2 807
40
Povidone-iodine Approved Phase 4 25655-41-8
41
Povidone K30 Approved, Experimental, Withdrawn Phase 4 9003-39-8 6917 131751496
42
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
43
Cefazolin Approved Phase 4 25953-19-9 33255
44
Dimercaprol Approved Phase 4 59-52-9 3080
45
Telavancin Approved Phase 4 372151-71-8 21014972 3081362
46
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
47
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
48
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
49
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
50
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897

Interventional clinical trials:

(show top 50) (show all 564)
# Name Status NCT ID Phase Drugs
1 Clinical and Microbiological Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients Unknown status NCT02117986 Phase 4 colistin
2 Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients: Randomized and Controlled Multicenter Clinical Trial. Unknown status NCT03438214 Phase 4 Vancomycin Continuous infusion;Vancomycin Intermittent infusion
3 Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
4 An Open-label, Randomized Equivalence Trial and Cost-effectiveness Analysis of Ertapenem Versus Other Carbapenems for Treatment of Extended -Spectrum Beta-Lactamase (ESBL)-Producing Gram-negative Bacterial Infections Unknown status NCT01297842 Phase 4 Ertapenem;Meropenem or Imipenem
5 Effectiveness of a Hydrophobic Dressing for Microorganisms' Colonization and Infection Control of Vascular Ulcers: An Open, Controlled, Randomized Study, With Blinded Endpoint (PROBE Trial): CUCO-UV Study Unknown status NCT03667937 Phase 4
6 Plasma Concentrations of Amoxicillin Administered in High-doses During the First Week of Treatment : Intra- and Inter-individual Variability, Factors Associated With Overdose and Adverse Events Unknown status NCT04070469 Phase 4 Amoxicillin
7 High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection Unknown status NCT02553083 Phase 4 Nexium 40 mg;amoxicillin 1.5 gr;doxycycline 200 mg;Nexium 20 mg;clarythromicin 500 mg;amoxicillin 1gr
8 Impact of Antibiotic Treatment Following Implantation of Cardiac Electronic Device on Patient's Outcome Unknown status NCT03148444 Phase 4 cefalexin 500 mg qid or roxithromycin 150 mg bid
9 Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy. Unknown status NCT01572597 Phase 4 10RAC+acetylcystein;10RAC+metronidazole
10 Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis Completed NCT00406198 Phase 4
11 Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants - A Study on Interactions by Nonsteroidal Anti Inflammatory Drugs (NSAIDs) With Fluconazole in Respect of Pharmacodynamic Endpoints With Urinary Excretion of Vasoactive Endobiotics Completed NCT02079298 Phase 4 Treatment with fluconazole.;2. Treatment with both fluconazole and Ibuprofen.;3. Treatment with ibuprofen.
12 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Completed NCT01968395 Phase 4 Caspofungin 70 mg
13 A Clinical Pharmacokinetic Study: Is Three Times Weekly Temocillin Appropriate for the Treatment of Severe Gram-negative Infections in Patients With ESRD Treated With Intermittent Hemodialysis? Completed NCT02285075 Phase 4 temocillin PK/PD in haemodialysis
14 Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections Completed NCT03397914 Phase 4 Colistimethate Sodium
15 Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections Completed NCT00147511 Phase 4 linezolid
16 Dispositivo Adsorbente Con Polymyxina B Immobilizzata Nello Shock Settico - Studio Clinico Randomizzato e Prospettico, Multicentrico Completed NCT00629382 Phase 4
17 Multicenter Open-label RCT to Compare Colistin Alone vs. Colistin Plus Meropenem Completed NCT01732250 Phase 4 Colistin;Meropenem
18 Extended-infusion Piperacillin-Tazobactam Versus Intermittent-Infusion Dosing Strategy in Critically Ill Patients With Suspected or Confirmed Bacterial Infections. Completed NCT04895657 Phase 4 Piperacillin/Tazobactam Continuous infusion;Piperacillin/Tazobactam Intermittent infusion
19 Intravenous to Oral Antibiotic Switch Therapy for Probable Neonatal Bacterial Infections: Clinical Efficacy, Safety and Cost-effectiveness Completed NCT03247920 Phase 4 Amoxicillin Clavulanate;Antibiotics
20 Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) Producing Bacteria Completed NCT00488189 Phase 4 Tazocin (pipercillin/tazobactam)
21 An Individually Randomised Trial of Rapid Diagnostic Tests in Rural Ghana Completed NCT00493922 Phase 4
22 Randomized, Multi-Center, Comparative Trial of Short-Course Empiric Antibiotic Therapy Versus Standard Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the Intensive Care Unit (ICU) Completed NCT00410527 Phase 4 Merrem
23 Skin Disinfection With Octenidine Dihydrochloride for the Prevention of Catheter-Associated Infections - A Double-Blind, Randomized, Controlled Trial Completed NCT00515151 Phase 4 0.1% Octenidine with 30% 1-propanol and 45% 2-propanol;74% Ethanol with 10% 2-propanol
24 Association of Antibiotic Utilization Measures and Control of ESBLs Producing Bacteria Completed NCT00478855 Phase 4 Tazocin (Piperacillin/Tazobactem)
25 Pharmacokinetics of Colistin in Critically-ill Patients With Acute Kidney Injury Who Receive Sustained Low-Efficiency Dialysis Completed NCT05586438 Phase 4 Colistin Sulfomethate
26 A Post Marketing Surveillance Study on the Safety and Effectiveness of Doripenem in the Therapy of Thai Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections Completed NCT00965848 Phase 4 Doripenem
27 A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Conjunctiva of Healthy Volunteers Following a Single Ocular Administration Completed NCT00564447 Phase 4 Azithromycin;Moxifloxacin
28 Randomized, Open-label, Comparative Study of Zosyn (Pip/Tazo [12g/1.5g]) Administered by Daily 24hr Continuous Infusion vs Zosyn (Pip/Tazo) [3g/0.375g]) q6h for the Treatment of Hospitalized Patients With Complicated Intra-abdominal Infection Completed NCT00044928 Phase 4 Piperacillin/Tazobactam
29 Peri-implantitis - Regenerative Treatment With Enamel Matrix Derivative (EMD). Clinical Effects, Microbial Profiles and Molecular Mechanisms. A Randomised Controlled Pilot Study. Completed NCT02500654 Phase 4
30 An Open Observational Study For The Rabeprazole Administration In Adult Subjects With Helicobacter Pylori (H. Pylori) Infection Completed NCT00216450 Phase 4 rabeprazole sodium
31 A Multi-Center, Open-Label, Randomized Study of the Pharmacokinetics of Azithromycin Versus Moxifloxacin in Conjunctiva and Aqueous Humor Following Single or Multiple Ocular Administration of AzaSite Ophthalmic Solution, 1% or Vigamox in Subjects Undergoing Routine Cataract Surgery Completed NCT00575380 Phase 4 AzaSite Eye Drops;Vigamox Eye Drops
32 A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Tears of Healthy Volunteers Following a Single Ocular Administration Completed NCT00575367 Phase 4 AzaSite (azithromycin ophthalmic solution);Vigamox (moxifloxacin hydrochloride ophthalmic solution)
33 Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections Completed NCT03233438 Phase 4 Dalbavancin;Usual Care
34 A Randomized Controlled Trial of Triple Therapy Versus Sequential Therapy Versus Concomitant Therapy as First Line Treatment for Helicobacter Pylori Infection Completed NCT02092506 Phase 4 10 day triple therapy;10 day sequential therapy;10 day concomitant therapy
35 An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months Completed NCT00555061 Phase 4 Retapamulin Ointment, 1%
36 Comparison of Amukin Versus Biseptine Use for Dressing Application of Epicutaneocavous Catheters for Nosocomial Infection Prevention Completed NCT00389558 Phase 4
37 Leukocyte Depletion of Autologous Whole Blood: Impact on Perioperative Infection Rate and Length of Hospital Stay for Hip Arthroplasty Patients Completed NCT00176124 Phase 4
38 An Open-Label, Two-Treatment, Two-Period, Randomized Cross-Over Study To Assess The Bioequivalence Between Commercial Doxycycline Carragenate And Monohydrate Tablet Formulations In Normal Healthy Male Subjects Completed NCT00939562 Phase 4 doxycycline monohydrate tablet;doxycycline carragenate tablet
39 A Phase IV Open-Label Pharmacokinetic Study of Minocycline for Injection Following a Single Infusion in Critically-Ill Adults (ACUMIN) Completed NCT03369951 Phase 4 Minocycline
40 A Single Site Prospective Randomized Controlled Trial Comparing Chlorhexidine Gluconate and Povidone-Iodine as Vaginal Preparation Antiseptics for Cesarean Section to Determine Effect on Bacterial Load Completed NCT03133312 Phase 4 Chlorhexidine Gluconate;Povidone-Iodine Scrub and Paint
41 A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly With Raxibacumab (GSK3068483) Completed NCT02339155 Phase 4 Diphenhydramine
42 Saccharomyces Boulardii in the Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients With Lower Respiratory Tract Infections Completed NCT05261152 Phase 4 drug product: capsules are containing S. boulardii, administered twice daily (250 mg)
43 Steroids for Corneal Ulcers Trial Completed NCT00324168 Phase 4 Antibiotics;Topical corticosteroid;Placebo
44 Association of Antibiotic Utilization Measures and Control of Extended-spectrum-lactamases (ESBLs) Completed NCT00254696 Phase 4 Extended-Spectrum-Lactamases (ESBLs)
45 A Prospective, Multi-Center, Open-Label Study to Compare the POCone® With the UBiT®-IR300 in Measurement of 13CO2/12CO2 Ratio in Breath Samples Collected From Pediatric Subjects Ages 3 to 17 Years With Upper Gastrointestinal Signs and Symptoms Completed NCT01623154 Phase 4
46 Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction Completed NCT01244698 Phase 4 Cefadroxil discontinued early;Cefadroxil until drain removal
47 Helicobacter Eradication to Prevent Ulcer Bleeding in Aspirin Users: a Large Simple Randomised Controlled Trial Completed NCT01506986 Phase 4 Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg;Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg
48 A Study Comparing Prospective Use of Imipenem/Cilastatin/Relebactam (IMI/REL) to Retrospective Data Using Meropenem/ Vabobactam (MVB) and Ceftazidime/Avibactam (CZA) in Treatment of Klebsiella Producing Carbapenemase Enterobacteriaceae Infections Recruiting NCT04785924 Phase 4 Imipenem+Relebactam
49 Short Course Antibiotic Treatment of Gram-negative Bacteremia: A Multicenter, Randomized, Non-blinded, Non-inferiority Interventional Study Recruiting NCT04291768 Phase 4
50 Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled Trial Recruiting NCT03671967 Phase 4 Piperacillin/tazobactam;Meropenem

Search NIH Clinical Center for Bacterial Infectious Disease

Cochrane evidence based reviews: bacterial infections

Genetic Tests for Bacterial Infectious Disease

Anatomical Context for Bacterial Infectious Disease

Organs/tissues related to Bacterial Infectious Disease:

MalaCards : Skin, Lung, Eye, Neutrophil, Liver, Whole Blood, Kidney

Publications for Bacterial Infectious Disease

Articles related to Bacterial Infectious Disease:

(show top 50) (show all 910)
# Title Authors PMID Year
1
Myeloid differentiation primary response gene 88 is required for the resolution of otitis media. 53 62
18986247 2008
2
Multicenter prospective study of procalcitonin as an indicator of sepsis. 53 62
15990980 2005
3
Cytokine and cytokine receptor polymorphisms in infectious disease. 53 62
10786965 2000
4
Advances of Mesenchymal Stem Cells Released Extracellular Vesicles in Periodontal Bone Remodeling. 62
36315196 2022
5
Canine brucellosis due to Brucella canis: description of the disease and control measures. 62
35766163 2022
6
Immunoprotective role of aloin and disease resistance in Labeo rohita, infected with bacterial fish pathogen, Aeromonas hydrophila. 62
36427124 2022
7
[A Case of Oropharyngeal Tularemia Mimicking Lymphoma During Pregnancy]. 62
36458719 2022
8
Biological Roles of Fibroblasts in Periodontal Diseases. 62
36359741 2022
9
Next-Generation Examination, Diagnosis, and Personalized Medicine in Periodontal Disease. 62
36294882 2022
10
Therapeutic Potential of Antimicrobial Peptide PN5 against Multidrug-Resistant E. coli and Anti-Inflammatory Activity in a Septic Mouse Model. 62
36129300 2022
11
Description and validation of a new set of PCR markers predictive of avian pathogenic Escherichia coli virulence. 62
35961274 2022
12
Epidemiology of scrub typhus in a tertiary care hospital of Southern Odisha: a cross sectional study. 62
36192256 2022
13
Genotyping Helicobacter pylori and fgf7 gene expression in gastric cancer. 62
35799083 2022
14
Pharmacokinetics of danofloxacin in freshwater crocodiles (Crocodylus siamensis) after intramuscular injection. 62
35582881 2022
15
Pharmacokinetic characteristics of danofloxacin in green sea (Chelonia mydas) and hawksbill sea (Eretmochelys imbricata) turtles. 62
35332549 2022
16
What is the evidence base of used aggregated antibiotic resistance percentages to change empirical antibiotic treatment? A scoping review. 62
34906718 2022
17
A Deep Modality-Specific Ensemble for Improving Pneumonia Detection in Chest X-rays. 62
35741252 2022
18
Infection and seroprevalence of Borrelia persica in domestic cats and dogs in Israel. 62
35534871 2022
19
Cytopathological and bacteriological studies on caseous lymphadenitis in cattle slaughtered at Bishoftu municipal abattoir, Ethiopia. 62
35120279 2022
20
First-degree atrioventricular block in 14-year-old child due to Lyme disease. 62
35544637 2022
21
Identifying potential natural inhibitors of Brucella melitensis Methionyl-tRNA synthetase through an in-silico approach. 62
35312681 2022
22
Detection of Leptospira interrogans in Wild Sambar Deer (Rusa unicolor), Brazil. 62
35182280 2022
23
The evolving story of Borrelia burgdorferi sensu lato transmission in Europe. 62
35122516 2022
24
Identifying chemolithotrophic and pathogenic-related gene expression within suspended sediment flocs in freshwater environments: A metatranscriptomic assessment. 62
34656597 2022
25
Prediction of Immune Infiltration Diagnostic Gene Biomarkers in Kawasaki Disease. 62
35755167 2022
26
All trans retinoic acid as a host-directed immunotherapy for tuberculosis. 62
35496824 2022
27
High-Throughput Sequencing Investigation of Bacterial Diversity in Chronic Suppurative Otitis Media and Middle Ear Cholesteatoma. 62
36193141 2022
28
A versatile isothermal amplification assay for the detection of leptospires from various sample types. 62
35291487 2022
29
Comparison of the biomechanical differences in the occlusal movement of wild-type and BMP9 knockout mice with apical periodontitis. 62
36324890 2022
30
Binding properties of the anti-TB drugs bedaquiline and TBAJ-876 to a mycobacterial F-ATP synthase. 62
36186842 2022
31
Antibacterial and antioxidant effect of ethanol extracts of Terminalia chebula on Streptococcus mutans. 62
34184430 2021
32
Biomacromolecules of chitosan - Bacopa saponin based LipL32 gene delivery system for leptospirosis therapy. 62
34273371 2021
33
Tuberculosis, an unusual source - a case report. 62
35733548 2021
34
A Case of Whipple Disease With Cutaneous Manifestations. 62
33606378 2021
35
Phlegmonous gastritis developed during chemotherapy for acute lymphocytic leukemia: A case report. 62
34435017 2021
36
The adapter protein Myd88 plays an important role in limiting mycobacterial growth in a zebrafish model for tuberculosis. 62
33559740 2021
37
A novel Vancomycin-Functionalized-Magnetic Graphene Composite for Use as a Near-Infrared-Induced Synergistic Chemo-Photothermal Antibacterial. 62
33984161 2021
38
Adaptation of gltA and ssrA assays for diversity profiling by Illumina sequencing to identify Bartonella henselae, B. clarridgeiae and B. koehlerae. 62
34296984 2021
39
The RyfA small RNA regulates oxidative and osmotic stress responses and virulence in uropathogenic Escherichia coli. 62
34043736 2021
40
Fluorescence polarization assay improves the rapid detection of human brucellosis in China. 62
33789762 2021
41
Seroprevalence of Bovine Brucellosis in Ethiopia: Systematic Review and Meta-Analysis. 62
33469511 2021
42
Structural and Molecular Dynamics of Mycobacterium tuberculosis Malic Enzyme, a Potential Anti-TB Drug Target. 62
33356117 2021
43
Increased Level of Interleukin-8 in Female Genital Tract After HP Eradication Lines. 62
33397248 2021
44
Discovery of Potent Inhibitors of Streptococcus mutans Biofilm with Antivirulence Activity. 62
33488963 2021
45
Evodiae fructus Extract Inhibits Interleukin-1β-Induced MMP-1, MMP-3, and Inflammatory Cytokine Expression by Suppressing the Activation of MAPK and STAT-3 in Human Gingival Fibroblasts In Vitro. 62
34504537 2021
46
Editorial: Tissue Remodeling in Health and Disease Caused by Bacteria, Parasites, Fungi, and Viruses. 62
33604310 2021
47
Campylobacteriosis in Poland in 2018-2019. 62
35543598 2021
48
Seroprevalence and risk factors of brucellosis and the brucellosis model at the individual level of dairy cattle in the West Bandung District, Indonesia. 62
33642780 2021
49
Case Report: Metagenomic Next-Generation Sequencing Confirmed a Case of Central Nervous System Infection With Brucella melitensis in Non-endemic Areas. 62
34595192 2021
50
[What does a general practitioner need to know about whooping cough?] 62
33300701 2020

Variations for Bacterial Infectious Disease

Expression for Bacterial Infectious Disease

Search GEO for disease gene expression data for Bacterial Infectious Disease.

Pathways for Bacterial Infectious Disease



Pathways directly related to Bacterial Infectious Disease:

# Pathway Source
1 Microbial modulation of RIPK1-mediated regulated necrosis Reactome 66

Pathways related to Bacterial Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 TNF IRAK4 IL6 IL1B IL17A IL10
2
Show member pathways
13.87 IL10 IL17A IL1B IL6 IRAK4 MYD88
3
Show member pathways
13.72 TNF TLR4 IL6 IL1B IL17A IL10
4
Show member pathways
13.71 CAMP CCR6 CRP CSF3 CXCL8 DEFB1
5
Show member pathways
13.53 TNF TLR4 TLR2 MYD88 IRAK4 IL6
6
Show member pathways
13.5 TNF TLR4 TLR2 MYD88 IRAK4 IL6
7
Show member pathways
13.39 CCR6 CSF3 CXCL8 IL10 IL17A IL1B
8
Show member pathways
13.38 CSF3 CXCL8 IFNG IL10 IL17A IL1B
9
Show member pathways
12.99 TNF TLR4 TLR2 MYD88 IRAK4 IL6
10
Show member pathways
12.85 TNF TLR4 TLR2 MYD88 IRAK4 IL6
11
Show member pathways
12.77 CXCL8 IL1B IL6 IRAK4 MYD88 TLR2
12
Show member pathways
12.75 TNF IL6 IL1B IL17A IL10 IFNG
13
Show member pathways
12.74 TNF TLR4 TLR2 MYD88 IRAK4 IL1B
14
Show member pathways
12.71 TNF IL6 IL1B IL17A IL10 IFNG
15 12.66 TNF TLR2 NOD1 MYD88 IRAK4 IL1B
16
Show member pathways
12.57 NOD2 NOD1 MYD88 IRAK4 IL1B
17
Show member pathways
12.46 TLR2 ELANE DEFB4A DEFB1 CCR6 CAMP
18
Show member pathways
12.45 TNF TLR4 TLR2 NOD2 NOD1 MYD88
19
Show member pathways
12.44 TNF TLR2 IL6 IL17A CXCL8 CSF3
20
Show member pathways
12.44 TNF TLR4 MYD88 IRAK4 IL6 IL1B
21
Show member pathways
12.42 CXCL8 DEFB4A IFNG IL1B IL6 IRAK4
22 12.32 TNF TLR4 TLR2 IL6 IFNG
23
Show member pathways
12.3 TLR4 TLR2 MYD88 IRAK4
24 12.3 TNF IL6 IL1B IL10 CXCL8
25
Show member pathways
12.28 TNF MYD88 IL17A IL10 IFNG
26 12.24 TNF IL6 IL1B IL10 IFNG
27 12.17 TNF TLR4 IL6 IL1B IFNG CXCL8
28 12.15 CSF3 IFNG IL10 IL6 TNF
29 12.13 TNF IL6 IL1B IL17A IL10 CXCL8
30
Show member pathways
12.06 TLR4 MYD88 IL6 IL17A CXCL8 CSF3
31 12.06 TNF IL1B IL17A IL10 IFNG CXCL8
32 12.05 IL6 IL1B IFNG CXCL8
33
Show member pathways
12.03 IFNG IL17A IL1B IL6 TLR2 TLR4
34 12.01 IL6 IL10 CXCL8 CCR6
35
Show member pathways
11.97 TNF TLR4 TLR2 IL6 IL1B IL17A
36 11.96 TNF IL1B IL17A IL10 IFNG CCR6
37 11.93 TNF IL6 IL1B IL10 IFNG
38 11.91 TNF TLR4 MYD88 IL6 IL1B CXCL8
39 11.89 TLR4 IL6 IL10 IFNG
40 11.88 TNF TLR4 IL6 IL10 IFNG CRP
41 11.85 CXCL8 IFNG IL10 IL6
42 11.85 IFNG IL17A IL1B IL6
43
Show member pathways
11.84 TNF IL6 IL1B IFNG CXCL8
44 11.84 TNF IL6 IL1B CXCL8 CSF3
45
Show member pathways
11.83 TNF IL1B IFNG
46
Show member pathways
11.81 IL6 CXCL8 CRP
47 11.81 IL6 IFNG CXCL8
48 11.77 TNF TLR4 MYD88 IRAK4 IL6 IL1B
49
Show member pathways
11.75 TNF IFNG CXCL8
50 11.74 IRAK4 MYD88 TLR4 TNF

GO Terms for Bacterial Infectious Disease

Cellular components related to Bacterial Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.07 TNF IL6 IL1B IL17A IL10 IFNG
2 extracellular space GO:0005615 9.77 CAMP CRP CSF3 CXCL8 DEFB1 DEFB4A

Biological processes related to Bacterial Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.7 CSF3 IL10 IL17A IL1B IL6 NOD2
2 signal transduction GO:0007165 10.64 CCR6 CSF3 CXCL8 IFNG IL10 IL1B
3 positive regulation of gene expression GO:0010628 10.58 CRP CXCL8 IFNG IL1B IL6 MYD88
4 innate immune response GO:0045087 10.58 CAMP CRP DEFB1 IL17A IRAK4 MYD88
5 apoptotic process GO:0006915 10.57 IFNG IL17A IL1B MYD88 NOD1 TLR2
6 inflammatory response GO:0006954 10.51 CRP CXCL8 IL17A IL1B IL6 MYD88
7 negative regulation of cell population proliferation GO:0008285 10.5 TNF TLR2 IL6 IL1B IL10 CXCL8
8 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.46 TNF TLR4 NOD2 NOD1 MYD88 IRAK4
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.4 TNF TLR4 TLR2 NOD2 NOD1 MYD88
10 positive regulation of DNA-binding transcription factor activity GO:0051091 10.39 CSF3 IL10 IL1B IL6 TNF
11 positive regulation of JNK cascade GO:0046330 10.38 TNF TLR4 NOD2 NOD1 MYD88 IL1B
12 defense response to bacterium GO:0042742 10.38 CAMP DEFB1 DEFB4A ELANE IL10 MYD88
13 defense response to Gram-negative bacterium GO:0050829 10.37 TLR4 IL6 IL17A DEFB4A DEFB1 CAMP
14 cytokine-mediated signaling pathway GO:0019221 10.36 MYD88 IRAK4 IL6 IL1B CSF3
15 positive regulation of inflammatory response GO:0050729 10.36 IFNG IL1B TLR2 TLR4 TNF
16 positive regulation of tumor necrosis factor production GO:0032760 10.36 TLR4 TLR2 NOD2 NOD1 MYD88 IL6
17 positive regulation of MAP kinase activity GO:0043406 10.35 ELANE IL1B NOD2 TLR4 TNF
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.35 TNF TLR4 TLR2 NOD2 NOD1 IL1B
19 positive regulation of smooth muscle cell proliferation GO:0048661 10.33 ELANE IL6 IRAK4 MYD88 TLR4 TNF
20 phagocytosis GO:0006909 10.32 ELANE MYD88 NOD2 TLR4
21 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 10.32 DEFB4A DEFB1 CXCL8 CAMP
22 JNK cascade GO:0007254 10.32 IL1B IRAK4 MYD88 NOD1 NOD2 TLR4
23 humoral immune response GO:0006959 10.31 TNF IL6 IFNG CCR6
24 positive regulation of interleukin-12 production GO:0032735 10.31 IFNG IL17A NOD2 TLR2 TLR4
25 I-kappaB kinase/NF-kappaB signaling GO:0007249 10.31 IL1B MYD88 NOD1 NOD2 TLR4 TNF
26 lipopolysaccharide-mediated signaling pathway GO:0031663 10.3 IL1B MYD88 TLR2 TLR4 TNF
27 cellular response to lipopolysaccharide GO:0071222 10.3 CAMP CSF3 CXCL8 IL10 IL1B IL6
28 positive regulation of phagocytosis GO:0050766 10.29 TNF NOD2 IL1B IFNG
29 regulation of insulin secretion GO:0050796 10.29 TNF IL6 IL1B IFNG
30 immune response GO:0006955 10.28 TNF TLR4 TLR2 IL6 IL1B IL17A
31 positive regulation of nitric oxide biosynthetic process GO:0045429 10.27 TNF TLR4 IL1B IFNG
32 positive regulation of interleukin-10 production GO:0032733 10.27 TLR4 TLR2 NOD2 IL6
33 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.27 TNF TLR4 NOD2 MYD88 IL6 IL17A
34 positive regulation of interleukin-1 beta production GO:0032731 10.27 TNF TLR4 NOD2 NOD1 MYD88 IL6
35 positive regulation of cytokine production GO:0001819 10.26 TNF IL1B IL10 IFNG
36 immune system process GO:0002376 10.25 IL17A IRAK4 MYD88 NOD1 NOD2 TLR2
37 positive regulation of macrophage cytokine production GO:0060907 10.25 TLR4 NOD2 NOD1 MYD88
38 response to lipopolysaccharide GO:0032496 10.25 ELANE IL10 IL1B MYD88 NOD2 TLR2
39 positive regulation of chemokine production GO:0032722 10.25 IFNG IL1B IL6 MYD88 TLR2 TLR4
40 negative regulation of type II interferon production GO:0032689 10.24 TLR4 NOD2 IL10
41 MyD88-dependent toll-like receptor signaling pathway GO:0002755 10.24 TLR4 TLR2 MYD88 IRAK4
42 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.23 TNF IL6 IL10
43 regulation of inflammatory response GO:0050727 10.23 TNF TLR4 NOD2 MYD88
44 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 10.23 IFNG NOD2 TLR2 TLR4
45 liver regeneration GO:0097421 10.22 TNF IL6 IL10
46 innate immune response in mucosa GO:0002227 10.22 NOD2 DEFB1 CAMP
47 microglial cell activation GO:0001774 10.22 TNF TLR2 IFNG
48 positive regulation of interleukin-17 production GO:0032740 10.22 IL6 MYD88 NOD2
49 negative regulation of neurogenesis GO:0050768 10.22 IL1B IL6 TNF
50 toll-like receptor signaling pathway GO:0002224 10.21 TLR4 TLR2 IRAK4

Molecular functions related to Bacterial Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopolysaccharide binding GO:0001530 9.8 TLR4 TLR2 CAMP
2 pattern recognition receptor activity GO:0038187 9.73 NOD1 NOD2 TLR2
3 lipopolysaccharide immune receptor activity GO:0001875 9.67 TLR4 TLR2
4 peptidoglycan binding GO:0042834 9.63 NOD1 NOD2 TLR2
5 cytokine activity GO:0005125 9.5 TNF IL6 IL1B IL17A IL10 IFNG
6 interleukin-1 receptor binding GO:0005149 9.43 MYD88 IRAK4 IL1B

Sources for Bacterial Infectious Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....